Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy.

ABSTRACT:

Background

Monoclonal antibodies directed at IgE demonstrate clinical efficacy in subjects with peanut allergy, but previous studies have not addressed the kinetics of the clinical response or the role of mast cells and basophils in the food-induced allergic response.

Objective

We sought to determine the kinetics of the clinical response to omalizumab and whether clinical improvement is associated with either mast cell or basophil suppression.

Methods

Subjects with peanut allergy were treated with omalizumab for 6 months and assessed for clinical and cellular responses. At baseline, subjects had a double-blind, placebo-controlled oral food challenge (OFC), skin prick test titration (SPTT), and basophil histamine release (BHR) to peanut. BHR was repeated at week 2 and

SUBMITTER: Savage JH 

PROVIDER: S-EPMC3935509 | biostudies-literature | 2012 Nov

REPOSITORIES: biostudies-literature